Seven Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
BioCryst Pharmaceuticals (NASDAQ:BCRX) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, BCRX also gets A’s. For more information, get Portfolio Grader’s complete analysis of BCRX stock.
This week, AMAG Pharmaceuticals‘s (NASDAQ:AMAG) ratings are up from a C last week to a B. AMAG Pharmaceuticals utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The stock price has risen 13% over the past month, better than the 2.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of AMAG stock.
The rating of Neurocrine Biosciences (NASDAQ:NBIX) moves up this week, rising from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Maxygen‘s (NASDAQ:MAXY) ratings are looking better this week, moving up to a B from last week’s C. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock has a trailing PE Ratio of 3.50. For more information, get Portfolio Grader’s complete analysis of MAXY stock.
Sangamo BioSciences (NASDAQ:SGMO) boosts its rating from a C to a B this week. Sangamo BioSciences is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. For more information, get Portfolio Grader’s complete analysis of SGMO stock.
This week, Allos Therapeutics‘s (NASDAQ:ALTH) ratings are up from a C last week to a B. Allos is a biopharmaceutical company focused on developing and commercializing small-molecule drugs that treat cancer. For more information, get Portfolio Grader’s complete analysis of ALTH stock.
BioMimetic Therapeutics (NASDAQ:BMTI) earns a B this week, jumping up from last week’s grade of C. BioMimetic Therapeutics engages in the development and commercialization of regenerative protein therapeutic products primarily used for bone and tissue regeneration, repair and healing of musculoskeletal injuries, and conditions affecting bones, tendons, ligaments, and cartilage. For more information, get Portfolio Grader’s complete analysis of BMTI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
